Literature DB >> 28777149

Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features.

Keluo Yao1, Weiqiang Zhao1, Saeed Bajestani1, Alejandro Gru1, Gregory Otterson2, Konstantin Shilo1.   

Abstract

Because of rarity, clinicopathologic and genomic profiles of noncutaneous malignant melanoma (MM) are not well characterized. In this study, we provide a detailed evaluation of 6 cases of MM presenting as thoracic midline malignancy. The tumors occurred in 6 white patients (5 males and 1 female; medium age, 71.5 y; range, 55 to 81 y). At presentation, the disease was confined to the chest (6/6) with 4 cases subsequently showing brain metastasis. All 6 tumors featured epithelioid and 1 case also spindle cell morphology. Three of 6 tumors had melanin and all 6 expressed melanocytic markers. Molecular characterization showed 2 of 6 tumors with BRAF"hot spot" genetic alterations (both with BRAFV600K) and 1 with NF1mutation. All 6 patients died of the disease within 1 year (mean survival, 4.8 mo). One patient showed a partial response to BRAF inhibitor. Our study shows that MM in this location has a spectrum of genetic alterations. The findings highlight the need for comprehensive next generation sequencing-based molecular testing to optimize targeted therapies of this aggressive malignancy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28777149     DOI: 10.1097/PAI.0000000000000546

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

1.  Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma.

Authors:  Keluo Yao; Weiqiang Zhao; Saeed Bajestani; Alejandro Gru; Gregory Otterson; Konstantin Shilo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02

2.  Systemic Effects of Segmental Vibration in an Animal Model of Hand-Arm Vibration Syndrome.

Authors:  Kristine Krajnak; Stacy Waugh
Journal:  J Occup Environ Med       Date:  2018-10       Impact factor: 2.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.